Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital grows, but more slowly than its trailing trend
Q1 FY2026 other working capital of $56.48K (cash outflow) rose 265.9% year over year, behind the +284.2% change in trailing-twelve-month other working capital. Over 3 fiscal years it compounded at +39.4% a year.
Context
- Other working capital increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +265.9% toward the trailing-twelve-month pace of +284.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- 412.88K USD
- Year-over-year change
- +439.3%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 412.88K | +439.3% |
| FY2024 | 2024-12-31 | 76.56K | -19.0% |
| FY2023 | 2023-12-31 | 94.54K | -38.0% |
| FY2022 | 2022-12-31 | 152.44K | +410.4% |
| FY2021 | 2021-12-31 | (49.11K) | — |
Other Working Capital vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's LTM Mar 2026 other working capital of $276.17K is the smallest of the 2 companies compared; the peer median is $1.5M.
- Its year-over-year change of +284.2% is the lowest of 2, against a peer median of +764.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.5M | +764.4% | — | — | |
| LTM Mar 2026 | $276.17K | +284.2% | +39.4% | — | |
| Peer median (excluding LIXT) | $1.5M | +764.4% | — | — | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.